Sara Kaffashian1, Christophe Tzourio2, Aïcha Soumaré2, Carole Dufouil2, Yicheng Zhu2, Fabrice Crivello2, Pauline Maillard2, Susanna Schraen-Maschke2, Bernard Mazoyer2, Luc Buée2, Stéphanie Debette2. 1. From INSERM U897 (S.K., C.T., A.S., C.D., Y.Z., S.D.), University of Bordeaux, France; Peking Union Medical College Hospital (Y.Z.), Beijing, China; CNRS-CEA UMR 5296 (F.C., B.M.), University of Bordeaux, France; University of California Davis (P.M.); CHRU de Lille (S.S.-M., L.B.), Lille, France; INSERM U837 (S.S.-M., L.B.), Lille, France; Department of Neurology (S.D.), Bordeaux University Hospital, France; Department of Neurology (S.D.), Boston University School of Medicine, Framingham Heart Study, Boston, MA. sara.kaffashian@inserm.fr. 2. From INSERM U897 (S.K., C.T., A.S., C.D., Y.Z., S.D.), University of Bordeaux, France; Peking Union Medical College Hospital (Y.Z.), Beijing, China; CNRS-CEA UMR 5296 (F.C., B.M.), University of Bordeaux, France; University of California Davis (P.M.); CHRU de Lille (S.S.-M., L.B.), Lille, France; INSERM U837 (S.S.-M., L.B.), Lille, France; Department of Neurology (S.D.), Bordeaux University Hospital, France; Department of Neurology (S.D.), Boston University School of Medicine, Framingham Heart Study, Boston, MA.
Abstract
OBJECTIVE: We investigated the relation of circulating plasma β-amyloid (Aβ) with MRI markers of small vessel disease (SVD) in dementia-free community persons. METHODS: Participants were 1,690 individuals aged 65 to 80 years from the Three-City Dijon Study. Plasma Aβ measurement and MRI examination were performed at baseline and after a 4-year follow-up. MRI markers of SVD included white matter hyperintensities (WMH), lacunes, and enlarged perivascular spaces. We examined the relation of plasma Aβ levels with MRI markers of SVD at baseline and with progression of WMH over follow-up (n = 1,057). We also assessed whether these relations were modified by vascular risk factors, notably blood pressure. RESULTS: Low plasma Aβ1-40 levels were associated with increased progression of WMH, and low Aβ1-42 with higher odds of extensive WMH progression over the follow-up (odds ratio = 1.66, 95% confidence interval = 1.16-2.38). Consistently low Aβ1-40 and Aβ1-42 levels on both measurements were associated with accelerated progression of WMH. These associations were modified by blood pressure levels but not the APOE ε4 genotype. CONCLUSIONS: Progression of WMH volume in dementia-free older persons is associated with levels of circulating plasma Aβ. These results reinforce the notion of an interrelation of vascular and neurodegenerative mechanisms in cerebral aging.
OBJECTIVE: We investigated the relation of circulating plasma β-amyloid (Aβ) with MRI markers of small vessel disease (SVD) in dementia-free community persons. METHODS:Participants were 1,690 individuals aged 65 to 80 years from the Three-City Dijon Study. Plasma Aβ measurement and MRI examination were performed at baseline and after a 4-year follow-up. MRI markers of SVD included white matter hyperintensities (WMH), lacunes, and enlarged perivascular spaces. We examined the relation of plasma Aβ levels with MRI markers of SVD at baseline and with progression of WMH over follow-up (n = 1,057). We also assessed whether these relations were modified by vascular risk factors, notably blood pressure. RESULTS: Low plasma Aβ1-40 levels were associated with increased progression of WMH, and low Aβ1-42 with higher odds of extensive WMH progression over the follow-up (odds ratio = 1.66, 95% confidence interval = 1.16-2.38). Consistently low Aβ1-40 and Aβ1-42 levels on both measurements were associated with accelerated progression of WMH. These associations were modified by blood pressure levels but not the APOE ε4 genotype. CONCLUSIONS: Progression of WMH volume in dementia-free older persons is associated with levels of circulating plasma Aβ. These results reinforce the notion of an interrelation of vascular and neurodegenerative mechanisms in cerebral aging.
Authors: Dana R Jorgensen; C Elizabeth Shaaban; Clayton A Wiley; Peter J Gianaros; Joseph Mettenburg; Caterina Rosano Journal: Am J Physiol Heart Circ Physiol Date: 2018-02-02 Impact factor: 4.733
Authors: A Vilar-Bergua; I Riba-Llena; C Nafría; A Bustamante; V Llombart; P Delgado; J Montaner Journal: J Cereb Blood Flow Metab Date: 2016-01 Impact factor: 6.200
Authors: Sara Shams; Juha Martola; Andreas Charidimou; Mykol Larvie; Tobias Granberg; Mana Shams; Maria Kristoffersen-Wiberg; Lars-Olof Wahlund Journal: J Am Heart Assoc Date: 2017-09-22 Impact factor: 5.501
Authors: Aniket Mishra; Ganesh Chauhan; Marie-Helene Violleau; Dina Vojinovic; Xueqiu Jian; Joshua C Bis; Shuo Li; Yasaman Saba; Benjamin Grenier-Boley; Qiong Yang; Traci M Bartz; Edith Hofer; Aïcha Soumaré; Fen Peng; Marie-Gabrielle Duperron; Mario Foglio; Thomas H Mosley; Reinhold Schmidt; Bruce M Psaty; Lenore J Launer; Eric Boerwinkle; Yicheng Zhu; Bernard Mazoyer; Mark Lathrop; Celine Bellenguez; Cornelia M Van Duijn; M Arfan Ikram; Helena Schmidt; W T Longstreth; Myriam Fornage; Sudha Seshadri; Anne Joutel; Christophe Tzourio; Stephanie Debette Journal: Brain Date: 2019-04-01 Impact factor: 13.501
Authors: Michelle R Caunca; Andres De Leon-Benedetti; Lawrence Latour; Richard Leigh; Clinton B Wright Journal: Front Aging Neurosci Date: 2019-06-27 Impact factor: 5.750
Authors: Julia A Scott; Meredith N Braskie; Duygu Tosun; Paul M Thompson; Michael Weiner; Charles DeCarli; Owen T Carmichael Journal: Front Aging Neurosci Date: 2015-12-01 Impact factor: 5.750